The NCCTG Oncology Nursing Board was formed in the spring of 1983 to promote and organize nursing interest, involvement, and participation in all logistics and scientific endeavors of the North Central Cancer Treatment Group. It is responsible for developing, coordinating, and directing oncology nursing activities within the NCCTG. The NCCTG Oncology Nursing Board exists to promote excellence in oncology nursing and research for improve patient care. Members develop, maintain, and expand in their roles as leaders in oncology nursing by coordinating the following endeavors: A. To develop and conduct oncology nursing research studies in conjunction with the NCCTG Cancer Control Program. B. To organize and support oncology nurse educational opportunities. C. To act as patient educators and advocates in clinical implementation. D. To ensure nursing membership on committees and in activities and allow opportunity to collaborate with other health care professionals. The Oncology Nursing Board is comprised of one nurse representative from each member institution. The Board meets twice a year in conjunction with the NCCTG meeting to plan nursing activities within NCCTG. The Board is co-chaired by an elected NCCTG oncology nurse and by a Research Base oncology nursing coordinator. Louise Hahn (Ann Arbor) has served from 1998-2000. Susan Quella has served as Research Base co-chair since 1993. The co-chairs: A. convene and conduct all nursing meetings, B. are responsible for coordination of NCCTG nursing activities, C. designate subcommittees are necessary D. keep all records of the Oncology Nursing Board E. facilitate communication between the Oncology Nursing Board and the Executive Committee. In addition to the Nursing Board meeting, the nursing co-chairs provide a three-hour Nurses Open Forum implementing an unstructured agenda to facilitate open discussion among all NCCTG nurses in attendance at the Group meetings. These Open Forums are a platform that fosters communication, networking, dissemination of information, problem solving, and identification of future projects. Currently, the NCCTG Nursing Board is involved in planning and executing minority recruitment strategies, studying QOL issues in NCCTG patients, developing our Spring 2000 conference entitled """"""""Geriatric Oncology,"""""""" and carrying out four Nursing Board clinical trials. Future plans include more integral implementation of the strategic plan into the activities of the Nursing Board, developing a system for sharing accrual and coordination strategies for chemoprevention protocols, and an expanded role in leading the development of studies in symptom management. NCCTG nurses commit to quality patient care; they coordinate, administrate, educate, and orchestrate patient care, clinical trials, and the clinical environment. Every Board member is truly a leader in oncology nursing in the NCCTG arena.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA025224-22
Application #
6482158
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1982-01-01
Project End
2005-12-31
Budget Start
Budget End
Support Year
22
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Schiff, David; Jaeckle, Kurt A; Anderson, S Keith et al. (2018) Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer 124:1455-1463
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Witzig, T E; LaPlant, B; Habermann, T M et al. (2017) High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). Blood Cancer J 7:e576
Brown, Paul D; Ballman, Karla V; Cerhan, Jane H et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060

Showing the most recent 10 out of 718 publications